Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors
In 2015, the first large-scale placebo-controlled trial designed to assess cardiovascular safety of glucose-lowering with sodium–glucose co-transporter 2 (SGLT2) inhibition in type 2 diabetes mellitus raised hypotheses that the class could favourably modify not only risk of atherosclerotic cardiovas...
Asıl Yazarlar: | Herrington, WG, Savarese, G, Haynes, R, Marx, N, Mellbin, L, Lund, LH, Dendale, P, Seferovic, P, Rosano, G, Staplin, N, Baigent, C, Cosentino, F |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
Wiley
2021
|
Benzer Materyaller
-
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
Yazar:: Giuseppe Rosano, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01) -
Effect of sodium-glucose Co-transporter 2 inhibitors on coronary microcirculation
Yazar:: Shaoxin Chen, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01) -
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Yazar:: Moran Gvili Perelman, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01) -
Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Yazar:: Herrington, W, ve diğerleri
Baskı/Yayın Bilgisi: (2022) -
Current developments in peritoneal glucose transport and sodium-glucose co-transporter 2 inhibitors during peritoneal dialysis
Yazar:: Fan Yang, ve diğerleri
Baskı/Yayın Bilgisi: (2023-11-01)